Wyeth and Ambrx, Inc. have formed a worldwide alliance to discover, develop, and commercialize protein drug candidates for three undisclosed targets. The alliance will utilize Ambrx’s recent breakthroughs in applying its protein medicinal chemistry platform to proteins produced in mammalian cells such as antibodies and antibody-toxin conjugates. Ambrx is eligible for payments from an upfront commitment, target loading fees and research funding, as well as preclinical, clinical, regulato...